lanthanum has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawaguchi, K; Kodama, R; Makino, M; Nagasawa, M; Nakamura, H; Shimojo, H | 1 |
| Berger, W; Chiba, P; Dornetshuber, R; Elbling, L; Heffeter, P; Jakupec, MA; Keppler, BK; Körner, W; Micksche, M; Pirker, C; Sutterlüty, H | 1 |
2 other study(ies) available for lanthanum and Adenocarcinoma
| Article | Year |
|---|---|
Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Microscopy, Electron, Scanning; Middle Aged; Neoplasms, Second Primary; Renal Insufficiency, Chronic; Spectrometry, X-Ray Emission; Stomach Neoplasms | 2015 |
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Small Cell; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Formazans; HL-60 Cells; Humans; Lanthanum; Lung Neoplasms; Molecular Structure; Neoplasm Proteins; Organic Anion Transporters; Organometallic Compounds; Phenanthrolines; Sensitivity and Specificity; Tetrazolium Salts | 2007 |